MedTrace Logo

A Long-term Safety Study of Once-daily Travatan

NCT00051168 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 502

Last updated 2011-10-07

Study results available
· View outcomes & findings →

Summary

Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

Travatan

Travoprost (0.004%) 1 drop each eye once daily

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00051168 on ClinicalTrials.gov